BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $178 from $176 and keeps a Buy rating on the shares. Based on a 5% consensus revenue beat in Q3, the firm increased its total company sales estimate by 2%-3% in 2025-26 driven by better net pricing for Auvelity in major depressive disorder, the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
- Axsome Therapeutics files automatic mixed securities shelf
- Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating